Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SHP2 inhibitor
Migoprotafib (GDC-1971; compound 199) is a selective SHP2 inhibitor that suppresses the MAPK/ERK signaling pathway. It exhibits antitumor activity and is under investigation for its potential in targeting SHP2-driven cancers. -
Microglial inhibitor
Inflachromene is a microglial inhibitor that exerts anti-inflammatory effects by directly binding to high mobility group box proteins HMGB1 and HMGB2. Through this interaction, it effectively downregulates the proinflammatory activities of HMGB proteins, leading to reduced microglial activation and neuronal damage. Inflachromene holds promise as a therapeutic candidate for the treatment of neuroinflammatory disorders, including neurodegenerative diseases and central nervous system injuries. -
ERK/p38 MAPK Inhibitor
Broussonin E is a phenolic compound with demonstrated anti-inflammatory properties. It exerts its effects by modulating macrophage activation, specifically through inhibition of the ERK and p38 MAPK signaling pathways while enhancing the JAK2–STAT3 pathway. This dual regulatory mechanism helps suppress pro-inflammatory responses and supports immune homeostasis. Broussonin E is a promising candidate for research into inflammation-related diseases, including atherosclerosis and other chronic inflammatory conditions. -
p38 MAPK Inhibitor
Licochalcone E is a flavonoid compound that functions as a p38 MAPK inhibitor. It effectively inhibits the transcriptional activities of NF-κB and AP-1 by disrupting AKT and MAPK activation pathways. This compound is valuable for research focused on inflammation, cancer, and signal transduction pathways, offering insights into cellular mechanisms influenced by MAPK signaling. -
p38 MAPK Inhibitor
AS1940477 is an orally active inhibitor of the p38 MAPK pathway, targeting both the p38α and p38β isoforms. It effectively reduces the production of pro-inflammatory cytokines, such as TNFα, IL-1β, and IL-6, in human synovial interstitial cells and relevant animal models of inflammation. This compound is a valuable tool for research aimed at understanding and treating inflammatory diseases. -
p38α MAPK Inhibitor
rel-Talmapimod hydrochloride is a selective inhibitor of p38α MAPK, exhibiting an IC50 of 9 nM. By targeting the p38α MAPK pathway, rel-Talmapimod hydrochloride effectively inhibits the secretion of pro-inflammatory factors, including TNFα, IL-1β, IL-6, and VEGF, while also blocking angiogenesis and osteoclast activation. This compound has demonstrated the ability to inhibit the proliferation of multiple myeloma cells and induce apoptosis. It is suitable for research applications involving various hematological malignancies, such as multiple myeloma and myelodysplastic syndrome. -
p38 MAP Inhibitor
R-03201195 is a highly selective inhibitor of p38 MAP kinase, demonstrating an IC50 of 0.7 nM for p38α. It effectively inhibits TNF-α production in THP-1 cells and IL-1β in human whole blood, with IC50 values of 0.25 nM and 0.57 nM, respectively. This reagent is valuable for research applications in inflammatory diseases, particularly rheumatoid arthritis. -
p38α MAPK Inhibitor
BMS-751324 is a selective inhibitor of p38α MAPK, a key regulator in the inflammatory response pathway. This compound demonstrates significant anti-inflammatory effects, as evidenced by its ability to reduce foot swelling and inhibit LPS-induced TNFα production in an arthritic rat model. BMS-751324 is suitable for research applications focused on inflammation, arthritis, and related pathways. -
p38α Inhibitor
P38α-IN-10 is a selective inhibitor of p38α with an IC₅₀ of 230 nM. It effectively suppresses TNF production induced by lipopolysaccharide (LPS), making it a valuable tool for research into inflammatory responses. This compound is particularly relevant for studying conditions such as rheumatoid arthritis and septic shock, contributing to a deeper understanding of their underlying mechanisms. -
p38α MAPK Inhibitor
Talmapimod hydrochloride is a selective inhibitor of p38α MAPK, exhibiting an IC50 of 9 nM. This compound effectively suppresses the secretion of pro-inflammatory cytokines, including TNFα, IL-1β, IL-6, and VEGF, while also inhibiting angiogenesis and osteoclast activation. Talmapimod hydrochloride demonstrates efficacy in inhibiting the growth of multiple myeloma cells and promoting apoptosis, making it a valuable tool for investigating various hematological malignancies, such as multiple myeloma and myelodysplastic syndromes. -
p38 MAPK Inhibitor
SR-318 is a selective inhibitor of p38 MAPK, exhibiting potent activity with IC50 values of 5 nM, 32 nM, and 6.11 µM for p38α, p38β, and p38α/β, respectively. This compound effectively reduces TNF-α release in whole blood, showing an IC50 of 283 nM. SR-318 is utilized in research focusing on anti-cancer and anti-inflammatory pathways, making it valuable for investigating therapeutic strategies in related diseases. -
p38 Inhibitor
TAT-MKK3b is a peptide inhibitor targeted at p38 mitogen-activated protein kinase (MAPK). It effectively inhibits p38 phosphorylation, contributing to its role in modulating cellular stress responses. TAT-MKK3b exhibits renal targeting, reactive oxygen species (ROS) scavenging, and the ability to mitigate ferroptosis. This compound has demonstrated potential in the improvement of acute kidney injury and may help prevent its progression to chronic kidney disease. -
p38/JNK Inhibitor
LL-Z1640-4 is a selective inhibitor of p38 and JNK signaling pathways, demonstrating significant efficacy in attenuating their activation in hepatocellular carcinoma (HCC) cells following MLK4 siRNA transfection. This compound effectively reduces reactive oxygen species (ROS) production associated with MLK4 knockdown and subsequently decreases apoptosis in these HCC cells. LL-Z1640-4 serves as a valuable tool for investigating the roles of p38 and JNK in cancer biology and therapeutic interventions. -
BCR-ABL/SRC/p38 Inhibitor
CHMFL-ABL-053 is a potent, selective inhibitor targeting BCR-ABL, SRC, and p38 kinases, exhibiting IC50 values of 70 nM, 90 nM, and 62 nM, respectively. This compound demonstrates significant antiproliferative activity, making it a valuable tool in cancer research, particularly in studies focusing on chronic myeloid leukemia and related malignancies. Its oral bioavailability enhances its utility in in vivo research applications. -
p38/CK1 Inhibitor
Casein kinase 1δ-IN-29 is a potent inhibitor of p38α and casein kinase 1, demonstrating IC50 values of 0.041 µM for p38α, 0.005 µM for CK1δ, and 0.447 µM for CK1ε. This compound effectively interrupts the cell cycle at the subG1 phase and induces apoptosis in AC1-M88 cells. It serves as a valuable tool in research applications focused on cell cycle regulation and apoptosis pathways. -
p38 MAPK Inhibitor
JNJ-49095397 is a selective inhibitor of p38 MAPK, targeting both the α and γ isoforms. This compound also exhibits inhibition of the SRC kinase family, particularly haematopoietic kinase (HCK). JNJ-49095397 demonstrates significant anti-inflammatory activities and is utilized in research focused on chronic obstructive pulmonary disease (COPD) and asthma. -
p38MAPK Inhibitor
SB 220025 is a selective inhibitor of p38 MAPK, operating through an ATP-competitive mechanism with an IC50 of 60 nM. This compound is effective in reducing the expression of the IL-8 gene in response to globular adiponectin, thereby decreasing inflammatory cytokine production and inhibiting angiogenesis. Additionally, SB 220025 demonstrates efficacy in preventing arthritis progression within chronic inflammatory disease models, making it a valuable tool for research on inflammation and related pathologies. -
P38-α/Syk Inhibitor
TOP1362 is a potent inhibitor targeting P38-α and Syk kinases, with Kd values of 26 nM and 18 nM, respectively. The compound demonstrates an IC50 of 14 nM in Src kinase activity assays, showcasing its efficacy in inhibiting P38-α, Src, and Syk. TOP1362 is applicable in research focused on dry eye syndrome and related pathways. -
p38MAPK Inhibitor
SB 220025 (tri(hydrochloride)) is a reversible, orally active, ATP-competitive inhibitor of human p38 MAPK, with an IC50 of 60 nM. This compound also exhibits inhibition of p56Lck and PKC with IC50 values of 3.5 μM and 2.89 μM, respectively. SB 220025 trihydrochloride effectively reduces IL-8 gene expression in response to globular adiponectin and diminishes inflammatory cytokine production, making it a valuable tool for studying inflammation and angiogenesis. Additionally, it has shown efficacy in preventing the progression of arthritis in chronic inflammatory disease models. -
ERK2/p38α MAPK Inhibitor
ERK2/p38α MAPK-IN-1 is a selective inhibitor targeting ERK2 and p38α MAPK, exhibiting an IC50 of 82 μM for ERK2. This compound binds allosterically to both ERK2 and p38α MAPK, influencing their activity through distinct mechanisms. It is primarily utilized in research concerning type 2 diabetes, contributing to studies aimed at understanding the molecular pathways involved in this condition. -
Selective p38α Inhibitor
AMG-548 dihydrochloride is a selective p38α inhibitor with a Ki of 0.5 nM, exhibiting moderate selectivity towards p38β (Ki = 36 nM) and over 1000-fold selectivity against p38γ and p38δ isoforms. This compound demonstrates potent inhibition of TNFα production in whole blood stimulated by LPS, with an IC50 of 3 nM. Additionally, AMG-548 dihydrochloride inhibits Wnt signaling by directly targeting Casein kinase 1 isoforms δ and ε, making it valuable for research in inflammation and signaling pathways. -
Selective p38α Inhibitor
AMG-548 hydrochloride is a selective inhibitor targeting p38α with a Ki of 0.5 nM and shows moderate selectivity for p38β (Ki=36 nM), while exhibiting over 1000-fold selectivity against p38γ and p38δ. This compound effectively inhibits TNFα production in whole blood stimulated by LPS, with an IC50 of 3 nM. Additionally, AMG-548 hydrochloride disrupts Wnt signaling through the direct inhibition of Casein kinase 1 isoforms δ and ε, making it a valuable reagent for studies in inflammation and cancer research. -
p38/CK1 Inhibitor
p38α inhibitor 8 selectively inhibits p38α MAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively. This compound is valuable for studies exploring cellular stress responses and inflammatory pathways, making it a potent tool in cancer research and immunology. Its ability to modulate these kinases presents opportunities for investigating therapeutic strategies in various diseases. -
p38/CK1 Inhibitor
p38α MAPK/CK1δ inhibitor-1 is a selective inhibitor targeting p38α MAPK and CK1δ, exhibiting IC50 values of 0.185 µM and 0.089 µM, respectively. This compound plays a crucial role in modulating cellular responses associated with stress and inflammatory pathways. Its inhibition of both kinases makes it a valuable tool for investigating signaling pathways and therapeutic strategies in various disease models. -
BChE/p38-α MAPK Inhibitor
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor targeting human butyrylcholinesterase (BChE) with an IC50 of 772 nM and p38 α MAPK with an IC50 of 191 nM. This compound significantly reduces the production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α in cellular models. BChE/p38-α MAPK-IN-1 demonstrates the potential to ameliorate cognitive impairments induced by scopolamine and alleviate spatial learning deficits in LPS-treated mice, making it a valuable tool for studying Alzheimer's disease by addressing cholinergic deficits and neuroinflammation. -
p38 MAPK Inhibitor
Chicanine is a lignan derived from Schisandra chinensis that functions as a selective inhibitor of p38 MAPK. It effectively inhibits LPS-induced phosphorylation of p38 MAPK, ERK 1/2, and IκB-α, demonstrating significant anti-inflammatory activity. This compound is valuable for research applications centered around inflammation, signaling pathways, and the modulation of MAPK-related processes. -
p38 MAPK Inhibitor
FR 167653 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), demonstrating significant suppression of pro-inflammatory cytokines such as TNF-α and IL-1β through targeted inhibition of p38 MAPK activity. This compound is effective in preclinical models for managing inflammation and provides therapeutic benefits in conditions related to trauma and ischemia-reperfusion injury. Its ability to modulate inflammatory responses makes it a valuable tool for research in inflammation and related disorders. -
p38 MAPK Inhibitor
Dilmapimod tosylate is a potent inhibitor of p38 mitogen-activated protein kinase (MAPK), a key regulator of inflammatory responses. This compound exhibits significant biological activity by reducing pro-inflammatory cytokine production, making it a valuable tool in studying inflammatory processes. It has potential applications in researching chronic inflammatory diseases, including chronic obstructive pulmonary disease (COPD). -
p38 MAPK Inhibitor
p38 MAPK-IN-2 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK). This compound effectively attenuates p38 MAPK signaling, leading to decreased phosphorylation of downstream targets involved in inflammatory responses. It is valuable for researchers studying cellular stress responses, cytokine signaling, and potential therapeutic effects in various inflammatory diseases and cancer. -
p38 MAPK Inhibitor
2-Phenylacetamide is a potent inhibitor of the p38 MAPK signaling pathway. This compound demonstrates significant anti-inflammatory, antioxidant, anti-hypertensive, and anti-fibrotic properties, making it a valuable tool for investigating various biological processes. Additionally, 2-Phenylacetamide is orally active, facilitating its use in in vivo research applications. -
p38 MAPK Inhibitor
p38 MAPK-IN-1 is a selective inhibitor of p38 MAPK, exhibiting an IC50 of 68 nM. This compound demonstrates sustained plasma levels, low clearance, and favorable bioavailability, making it an effective tool for biological research. p38 MAPK-IN-1 is primarily utilized in studies investigating inflammatory responses, apoptosis, and various disease states involving p38 MAPK signaling pathways. -
p38 MAPK Inhibitor
Doramapimod hydrochloride is a selective inhibitor of p38 MAPK, a key regulator in inflammatory responses. This compound effectively attenuates the production of pro-inflammatory cytokines, including TNF-α and IL-1β, in response to LPS, LTA, and PGN stimulation. Its potent anti-inflammatory properties make Doramapimod hydrochloride valuable for researching various autoimmune diseases and inflammatory pathways. -
P38 MAPK Inhibitor
2-Oleoxyphenethyl phosphocholin is an inhibitor of the p38 MAPK pathway, which plays a critical role in cellular stress responses and inflammatory processes. This compound exhibits significant anticancer activity, potentially through its interaction with the lipid-binding pocket of p38 MAPK. Its broad-spectrum anti-tumor properties make 2-Oleoxyphenethyl phosphocholin a valuable tool for research in cancer biology and therapeutic development. -
p38α MAPK Inhibitor
p38-α MAPK-IN-4 is a selective inhibitor of p38α MAPK, exhibiting an IC50 value of 1.5 µM. This compound demonstrates significant efficacy in the prevention of mechanical allodynia in vivo, making it a valuable tool for research into pain mechanisms and inflammatory responses. Its specificity and potency render it suitable for investigating the role of p38α MAPK in various biological contexts, including neurobiology and chronic pain studies. -
p38α Inhibitor
P38α-IN-11 is a selective inhibitor of p38α, exhibiting a KD value of 586 nM. This compound is primarily utilized in research investigating cervical cancer, enabling studies on the modulation of p38α signaling pathways and their implications in tumorigenesis. Its inhibitory effects make it a valuable tool for elucidating the role of p38α in cancer biology. -
p38 Inhibitor
p38 Kinase Inhibitor 4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which plays a crucial role in mediating cellular responses to stress and inflammation. This compound demonstrates significant anti-inflammatory activity, making it valuable for research in inflammation-related diseases and cellular signaling pathways. It serves as an essential tool for studying p38 MAPK's role in such processes and evaluating potential therapeutic strategies. -
p38 MAPK Inhibitor
p38 MAPK-IN-9 is a selective inhibitor of p38α mitogen-activated protein kinase (MAPK), demonstrating an IC50 value of 9.6 nM. This compound exhibits potent anti-inflammatory activity, making it a valuable tool for research into inflammatory diseases, including rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD). Its oral bioavailability and high selectivity position p38 MAPK-IN-9 as an effective reagent for exploring the role of p38 MAPK in various biological pathways and therapeutic interventions. -
p38 MAPK Inhibitor
AZD 6703 is a selective inhibitor of p38α MAP kinase, targeting the MAPK pathway involved in inflammatory responses. It demonstrates significant anti-inflammatory activity, making it a valuable tool for investigating inflammatory diseases and related therapeutic interventions. Researchers can utilize AZD 6703 to explore p38 MAPK's role in various cellular processes and to develop strategies for modulating inflammation. -
p38 Inhibitor
L-167307 is a potent p38 kinase inhibitor that exhibits anti-inflammatory properties. It has been shown to significantly reduce secondary paw swelling in rat models of adjuvant-induced arthritis. This compound is valuable for research applications involving inflammation and pain pathways, facilitating the study of p38-mediated signaling in various disease models. -
PLK1/p38γ Inhibitor
PLK1/p38γ-IN-1 is a multitarget inhibitor that selectively targets PLK1 and p38γ kinases. This compound has demonstrated the ability to inhibit cell proliferation in human hepatocellular carcinoma and hepatoblastoma cell lines in vitro. PLK1/p38γ-IN-1 is valuable for research focused on cancer biology and the modulation of cell cycle pathways. -
p38 MAPK Inhibitor
Ganoderterpene A is a potent inhibitor of p38 MAPK, demonstrating significant anti-inflammatory and anti-apoptotic activity. It effectively attenuates LPS-induced inflammation and apoptosis by suppressing the MAPK and TLR-4/NF-κB signaling pathways in BV-2 cells. This compound is valuable for research applications focused on neuroinflammation and cellular stress responses. -
P38 MAPK Inhibitor
2-Stearoxyphenethyl phosphocholin is a potent inhibitor of p38 MAPK, a key regulator of inflammatory and stress response pathways. This compound demonstrates significant anticancer activity and may selectively interact with the lipid-binding pocket of p38 MAPK, influencing its function. Due to its broad-spectrum anti-tumor properties and lipid-modulating effects, it is applicable in cancer research and studies focused on metabolic regulation. -
p38α inhibitor
p38-α MAPK-IN-5 is a potent inhibitor of p38α MAPK, exhibiting competitive affinity with an IC50 of 0.1 nM against p38α, and 0.2 nM for p38β, while displaying reduced efficacy toward p38γ and p38δ. This compound demonstrates significant anti-inflammatory properties, making it a valuable tool for researching inflammatory pathways associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD). Its specificity for p38α underscores its potential utility in studies aimed at elucidating the role of this kinase in inflammatory responses and related therapeutic interventions. -
p38 MAP Inhibitor
BIRB-1017 is a selective inhibitor of p38 MAP kinase, a key regulator in the inflammatory response. It demonstrates significant biological activity by modulating cytokine production and cellular signaling pathways associated with inflammation. This compound is suitable for use in research focused on understanding p38 signaling in various inflammatory diseases and therapeutic interventions. -
p38 MAP Kinase Inhibitor
p38 MAPK-IN-10 is a potent inhibitor of p38 MAP kinase, exhibiting an IC50 of 570 nM. This orally active compound shows promise in the study of chronic inflammatory diseases, including rheumatoid arthritis and Crohn’s disease. Its mechanism of action targets the p38 MAPK signaling pathway, making it a valuable tool for researchers investigating therapeutic approaches to modulate inflammation. -
p38α Inhibitor
R-130823 is a highly selective p38α inhibitor that exhibits an IC50 of 22 nM specifically against p38α, with minimal activity towards p38β (IC50 of 820 nM) and no significant interaction with p38γ or p38δ. This compound effectively downregulates cartilage degradation and inflammatory mediators, including the inhibition of MMP-13, MMP-1, and PGE2 release. R-130823 demonstrates therapeutic potential in reducing hind paw swelling, alleviating hyperalgesia, and impeding the progression of arthritis. It is particularly relevant for research studies focusing on osteoarthritis and rheumatoid arthritis. -
p38 Kinase Inhibitor
p38 Kinase Inhibitor 5 (AA6) selectively targets p38 MAP kinase, exhibiting a potent inhibitory effect with an IC50 of 403.57 nM. This compound is known for its significant anti-inflammatory activity, making it a valuable tool for research in inflammatory disease models and studies related to cytokine signaling pathways. Its role in modulating p38 kinase activity can provide insights into the mechanistic understanding of various pathological conditions. -
p38 MAP Kinase/Phosphodiesterase 4 Inhibitor
CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4, exhibiting potent anti-inflammatory and anti-allodynic effects. This compound significantly decreases the production of the proinflammatory cytokine IL-6 while elevating levels of the anti-inflammatory cytokine IL-10 in rat models. Additionally, CBS-3595 effectively mitigates paw edema in the Complete Freund’s adjuvant-induced arthritis model, making it a valuable tool for investigating potential therapies for autoimmune diseases. -
p38α Inhibitor
p38α inhibitor 7 is a potent inhibitor of the p38α mitogen-activated protein kinase, a key regulator of inflammation and stress responses. This compound demonstrates significant biological activity by effectively modulating the p38α pathway, making it applicable in studies exploring inflammatory diseases and neurological disorders. Its favorable pharmacokinetic properties enhance its potential for oral administration in therapeutic research. -
p38 MAP Inhibitor
AW-814141 is a selective and orally active inhibitor of p38 MAP kinase, demonstrating IC50 values of 100 nM for p38-α and 158 nM for p38-β isoforms. This compound effectively reduces TNF-α production induced by LPS and demonstrates a dose-dependent inhibition of paw edema in rat models. AW-814141 serves as a valuable tool in studying anti-inflammatory mechanisms and has potential applications in researching inflammatory diseases, including rheumatoid arthritis.
